Nuvectis Pharma, Inc. NVCT Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $4.11M+11.6% | $5.09M+13.1% | $5.77M+105% | $3.61M+22.8% | $3.68M+38.3% | ||
| $2.15M+14.1% | $2.53M+29.6% | $2.02M+31.2% | $2.98M+75.4% | $1.89M+8.8% | ||
| -$6.26M-12.4% | -$7.62M-18.1% | -$7.79M-78.8% | -$6.6M-42.0% | -$5.57M-26.7% | ||
| -$6.05M-13.5% | -$7.31M-17.1% | -$7.46M-79.7% | -$6.33M-43.0% | -$5.33M-27.8% | ||
| -$0.26+3.7% | -$0.31+13.9% | -$0.44-83.3% | -$0.30-15.4% | -$0.27-8.0% | ||
| -$0.26+3.7% | -$0.31+13.9% | -$0.44-83.3% | -$0.30-15.4% | -$0.27-8.0% | ||
| 23.4M+17.4% | 21.8M+27.5% | 22.7M+31.9% | 21.4M+26.4% | 19.9M+20.4% | ||
| 23.4M+17.4% | 21.8M+27.5% | 22.7M+31.9% | 21.4M+26.4% | 19.9M+20.4% | ||
| $210K-11.0% | $303K+50.7% | $332K+61.2% | $261K+21.4% | $236K+4.9% | ||
| -$6.26M-12.4% | -$7.62M-18.1% | -$7.79M-78.8% | -$6.6M-42.0% | -$5.57M-26.7% | ||
| -$6.26M-12.4% | -$7.62M-18.1% | -$7.79M-78.8% | -$6.6M-42.0% | -$5.57M-26.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Nuvectis Pharma, Inc. profitable?
- Nuvectis Pharma, Inc. is not currently profitable: it reported a net loss of $27.2M over the trailing twelve months.
- What is Nuvectis Pharma, Inc.'s earnings per share?
- Nuvectis Pharma, Inc.'s diluted EPS over the trailing twelve months is $-1.31.
- Where does Nuvectis Pharma, Inc.'s income statement data come from?
- Every line is extracted from Nuvectis Pharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.